- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00939900
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head (EZAPCOFH)
June 7, 2015 updated by: Kyung-Hoi Koo, Seoul National University Bundang Hospital
Multicenter, Open-labeled, Randomized Clinical Trial to Determine the Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head
The purpose of this study is to test the effect of zoledronic acid over 2 years in preventing early collapse and progression of joint dome depression (≥ 2 mm by X-ray) of the femoral head in patients with large (> 30%: criteria according to Kim et al) nontraumatic osteonecrosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Until now, the best treatment option in early (precollapse) large osteonecrosis femoral head is vascularizing fibular graft.
However, it requires high microsurgical technique.
Also it needs very long operation time (3-6hours), and morbidity associated with surgery is not low.
In early stage osteonecrosis, osteoclasts are activated and resorb the necrotic portion of bone and osteoblasts are followed to lay down new bone.
This process can weaken the bone function to support loading and can lead to collapse of bone.
Bisphophonate can inhibit this osteoclastic bone resorption and enhance osteoblastic new bone formation.
Recently, everyday oral intake of alendronate with vitamin D and calcium had a high success rate to prevent the collapse and decrease of hip joint pain in a short-term follow-up.
However, the compliance or adherence to everyday oral intake is questionable.
Moreover, the exact comparison based on MRI according to various classifications is not available currently.
There is no report about the effect of zoledronic acid to prevent early collapse and progression of joint dome depression (≥2 mm by X-ray) of the early stage large nontraumatic osteonecrosis of the femoral head or its effect on MRI signal change after infusion of zoledronic acid in noncollapsed cases (estimated about 30% of cases) The investigators need a controlled randomized multicenter interventional study about the efficacy of bisphophonates in the treatment of ONFH.
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi-do
-
Seongnam-Si, Gyeonggi-do, Korea, Republic of, 463-707
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient who agree to clinical trial
- Patient who are more than 18 years of age
- Osteonecrosis of the femoral head
- Steinberg stage I, II non traumatic osteonecrosis of femoral head
- Necrotic area of > 30% (HJ Kim et al )
- JIC (Japanese Investigation Committee): C1 or C2 lateral lesion (by X-ray or MRI)
Exclusion Criteria:
- Patients who are pregnant (patients who are of child bearing potential who are not practicing a reliable contraceptive method (oral, subcutaneous, mechanical, or surgical contraception)
- Patients who have contraindicated condition to zoledronic acid such as chronic renal failure (calculated creatinine clearance less than 35.0 ml/min), severe heart disease such as atrial fibrillation, sensitive to bisphosphonates and hypocalcemia (serum calcium less than 8 mg/dl or 2.0 mmol/L)
- Patients who have collapsed lesion including subchonral fracture
- Patients who have multiple lesion of osteonecrosis of femoral head
- Patients who received other kinds of bisphophonates or anabolic agents before zoledronic acid use
- Patients with any medical or psychiatric condition which, in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial per protocol
- Patients who are considered potentially unreliable and patients who may not reliably attend study visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control
control group
|
|
Experimental: aclasta
aclasta group
|
Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Femoral Head Collapse Within 24 Months
Time Frame: Measurements were done at 6, 12, 24 months
|
Measurements were done at 6, 12, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collpase Rate of Femoral Head
Time Frame: Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Change of HHS (Harris Hip Scores), WOMAC Score, SF-36
Time Frame: Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Time to Collapse of Femoral Head
Time Frame: Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Time to Total Arthroplasty or Joint Preserving Surgery
Time Frame: Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kyung-Hoi Koo, Professor, Seoul National University Bundang Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
July 14, 2009
First Submitted That Met QC Criteria
July 14, 2009
First Posted (Estimate)
July 15, 2009
Study Record Updates
Last Update Posted (Estimate)
July 2, 2015
Last Update Submitted That Met QC Criteria
June 7, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CZOL446HKR08T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Avascular Necrosis of Femoral Head
-
Universidad Autonoma de MadridCompletedAvascular Necrosis of the Femoral HeadItaly, France, Germany, Spain
-
University Hospital, Basel, SwitzerlandWithdrawnAvascular Necrosis of the Femoral Head
-
R-BioSMG-SNU Boramae Medical CenterCompletedAvascular Necrosis of the Femoral HeadKorea, Republic of
-
Zimmer BiometActive, not recruitingAvascular Necrosis of the Femoral HeadUnited States
-
Johns Hopkins UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsNot yet recruitingOsteonecrosis of the Femoral Head | Avascular Necrosis of the Femoral HeadUnited States
-
Global Stem Cell Center, BaghdadRecruitingAvascular Necrosis of the Femoral HeadIraq
-
National Health Research Institutes, TaiwanUnknown
-
The Hospital for Sick ChildrenTerminatedFemoral Head Avascular NecrosisCanada
-
Zimmer BiometRecruitingOsteoarthritis, Hip | Avascular Necrosis of Hip | Post-traumatic; Arthrosis | Avascular Necrosis of the Femoral HeadUnited States, Denmark, Japan, Netherlands, Norway, Sweden
-
Banc de Sang i TeixitsEuropean Regional Development Fund; Ministerio de Sanidad, Servicios Sociales... and other collaboratorsCompleted
Clinical Trials on zoledronic acid (aclasta)
-
Novartis PharmaceuticalsWithdrawnProsthetic Fixation After Cementless Total Hip ArthroplastyChina
-
Carmen Gómez-VaqueroTerminated
-
NovartisWithdrawn
-
Oslo University HospitalSykehuset Ostfold; Betanien HospitalTerminatedStress Fracture Foot | Stress Fracture AnkleNorway
-
The University of Hong KongPrince of Wales Hospital, Shatin, Hong Kong; Queen Mary Hospital, Hong Kong; United... and other collaboratorsRecruitingPneumonia | Hip FracturesHong Kong
-
University of Sao Paulo General HospitalCompleted
-
Novartis PharmaceuticalsCompletedMale OsteoporosisRussian Federation, Argentina, Switzerland, United Kingdom, Germany, Belgium, Czechia, Finland, Spain, Brazil, Romania, Hungary, Denmark, Poland, Norway, Sweden, Austria, South Africa, Slovakia, Australia, Iceland, Italy, Portugal
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
-
Aristotle University Of Thessaloniki251 Hellenic Air Force & VA General Hospital; 424 General Military HospitalCompletedPostmenopausal OsteoporosisGreece
-
University of OuluNovartis PharmaceuticalsCompleted